VRC 018: A Phase I Dose Escalation, Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Phase: PHASE1
Conditions: Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Official Title: A Phase I Dose Escalation, Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, 
Tolerability and Immunogenicity of a HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults 
 
ClinicalTrials.gov Identifier: NCT03783130 
 
Document Type: 
• 
Redacted Final Version of the Study Protocol (Statistical Analysis Considerations located in 
Section 6 of the Protocol)  
• 
Redacted Final Version of IRB-approved Informed Consent 
 
Document/Date: 
• 
Protocol Version 3.0: September 3, 2019 
• 
Version 3.0 IRB-approved Informed Consent (IRB approval: September 30, 2019)